|
|
| Acquisition of MaSTherCell Positions Catalent as Premier Partner for Advanced Biotherapeutics, Now Including Cell Therapy | |
|
|
| | | Catalent has acquired MaSTherCell, a leading, technology-focused cell therapy development and manufacturing partner.
In combination with Catalent’s deep experience in viral vector scale-up and production, MaSTherCell’s expertise in both autologous and allogeneic cell therapy development and manufacturing positions Catalent as a full-service partner for cell immunotherapies including CAR-T and beyond. The acquisition adds to Catalent’s network MaSTherCell’s 25,000 square-foot clinical services facility in Gosselies, Belgium, and its 32,000 square-foot facility in Houston, Texas. |
|
---|
| |
|
| Catalent will leverage its resources and expertise in build-outs, scale-up and commercial manufacturing to support the already underway expansion at both locations. |
|
| |
|
|
|
|
| | | Natural Products Expo West Join Catalent in Anaheim, California for Natural Products Expo West. Visit our booth 4183 from March 3 – 7 and learn about our growing capabilities to support plant-based dosage forms for the nutritional supplement industry. Learn about our Vegicaps® capsules solution for consumers seeking a seeking an alternative to animal-derived gelatin capsules. |
|
---|
| |
|
|
|
|
| Biologics Consulting Event in Santa Clara, California
|
|
| |
|
| On Wednesday, March 11, Catalent Biologics will host a consultant dinner event titled “Building Stronger Consulting Relationships to Advance Biologic Development Together.” The evening networking event will consist of dinner and presentations around Catalent’s strategic growth plans, recent platform innovations, and the latest technology investments to accelerate development programs. |
|
| |
|
|
|
|
| Catalent to Host Hot Melt Extrusion Workshop with Evonik
At an interactive workshop on March 12 at Catalent’s Somerset New Jersey facility, Catalent and Evonik will present, “A Deep Dive into the Technologies for Advanced Formulation and Targeted Delivery.” The event will consist of informative discussions on the role of hot melt extrusion in bioavailability enhancement. Learn from both companies expertise and capabilities, and how Catalent can provide guidance on the most suitable technology for development programs. |
|
| |
|
|
|
|
| | | Achieving Integrated Biologics Development
In partnership with One Nucleus, the U.K.’s Cambridge-London life science membership organization, this full day event on March 12 in London, will focus on sterile and biologics products, exploring how a comprehensive development, clinical and commercial-scale manufacturing and finished product supply solution has the potential to improve biopharmaceutical yield with reduced cost and time. Register today for this complimentary event. |
|
---|
| |
|
|
|
|
| | | Clinical Trial Supply Europe 2020
Join us at the 21st Clinical Trial Supply Europe event on March 11 – 12 and stop by our stand 32 to speak with our experts. Don’t miss our speaking presentations. On March 12 starting at 9:30 a.m., when Paul Ingram, Ph.D., Global Director, Strategic Development and Innovation, Clinical Supply Services will present: |
|
---|
| |
|
| Beyond Brexit: What Now for Clinical Supply Services across Europe. On the same day at 10:30 a.m., Keith Krenitsky, Global Director, Commercial Drug Sourcing will present: How Thoughtful Protocol Design Can Reduce Comparator Sourcing Cost, Timelines, Complexity & Risk. |
|
| |
|
|
|
|
| | | Outsourcing in Clinical Trials Isreal 2020
Visit us in Tel Aviv Israel March 17 - 18. Talk with our experts at booth 19. Attend our speaking presentation and hear Stephanie Graham, Regional Manager, Clinical Supplies Management present Proactive Strategies to Identify Clinical Supply Risks and Avoid Study Delays on March 17 at 11:30 a.m. |
|
---|
| |
|
|
|
|
| | | DCAT Week
Come and network with Catalent experts during DCAT Week, from March 23 – 26 in New York City. Don’t miss Catalent on Monday, March 23 at the DCAT Member Announcement at the NY Marriott East Side, where Mike Grippo, Sr. VP, Strategy and Corporate Development will presenting from 10:55 - 11:05 a.m. on the company’s $315-million acquisition of MaSTherCell. Schedule a meeting with our experts this week |
|
---|
| |
|
|
|
|
| | | Clinical Trial Supply New England
Join us in Boston Massachusetts March 24 - 25. Speak with our experts at booth 20 and hear Nicole Gray, Director of Strategic Supply Solutions, present "DTP Clinical Supply: Industry Perceptions & Practical Applications.” at 9:00 a.m. on March 24.
|
|
---|
| |
|
|
|
| A Catalyst in Drug Development | |
|
|
| Ariana Low Product Development, Principal Formulations Scientist Ph.D. |
|
| |
|
| | | Ariana Low specializes in formulation development of solid oral dosage forms at Catalent’s Schorndorf Germany facility. She helps bring molecules from Phase 1 to scale up and production by applying development tools employing Quality-by-Design principles from the ICH guidelines as part of the quality risk management system. Discover what drives her passion for formulation development, excipient optimization and quality assurance. Access her published works and additional content to help in your formulation development. |
|
---|
| |
|
|
|
| | | BIOLOGICS Executive Summary: “From Basics to Best Practices: Exploring Bioassays and Binding Assays” - Get expert insights into bioassays and binding assays, where they intersect, how they differ, and why developers would use one over another. Article: “Strategies for Testing Host Cell Proteins” - Catalent Biologics’ Michael Sadick, Ph.D., Principal Scientist, and Todd Stone, Ph.D., Senior Manager, give their insights about host cell protein testing and the tools that Catalent Biologics uses to monitor HCPs, with the goal of removing them from the biologic. Poster: “A Brief Evaluation of the Impact of Thermal, Shear, and Light Stress on Adalimumab” - The propensity of a protein to degrade under stress can vary widely among proteins and is important to understand in pharmaceutical development. In this poster, a model protein, adalimumab, was tested by a limited set of techniques after subjection to thermal, shear and light stresses. |
|
---|
| |
|
|
| | | CLINICAL SUPPLY / CLINICAL SERVICES Webinar: “Age-Appropriate Formulation Development for Pediatric Trials: Challenges and Considerations” - In this webinar, industry experts discuss the recent advances, challenges and considerations in pediatric drug development. Real-life examples presented by the experts illustrate the impact of age-appropriate dose forms for pediatrics and highlight insights into the caregiver perspectives. eBook: “Drug Design and the Patient Journey” - This eBook features insights from experts in the industry on patient-centric drug development challenges and strategies on advancing drug design and development effectively. Article: “Placing Patients at the Center of Drug Design” – In this article, experts from Catalent discuss the ways drug developers can bring patient insights into the design of their drug products to potentially improve patient acceptance and adherence. |
|
---|
| |
|
|
| | | ORAL DRUG DELIVERY Webinar: “Optimizing Spray Drying Strategies for Commercial Pharmaceutical Manufacturing” - The use of spray drying to manufacture amorphous dispersions is continuing to grow. Watch the webinar to learn how integrated services can minimize risk and save cost and time on development and manufacturing process. Article: “Planning Successful Launches” - Developing and bringing a new drug to market is a long, expensive and uncertain process. Read this article published by Pharmaceutical technology to learn proven strategies for a successful product launch, including cross-functional team collaboration, risk management and using the right project management tools. Case Study: “Commercial Scale-Up on Fluid-Bed Wurster Coating” – This case study presents a pharmaceutical company who was interested in scaling-up a multi-particulate, modified-release product to a commercial scale using fluid bed bottom-spray (Wurster) coating. Catalent was able to perform the technology transfer from small-scale to the desired 10x commercial scale. |
|
---|
| |
|
|
| | | CONSUMER HEALTH Video: “Consumer Health Capabilities – Why Choose Catalent” - Whether you are searching for a more enjoyable dosage form to increase consumer compliance or better formulations to improve label claims, Catalent has the right technology to support your innovation strategies. Watch this short video to learn how we can be your innovation partner. Webinar: “OTC Innovation to Avoid Stagnation” – What are the critical factors for OTC products to achieve consumer engagement and retail success? Watch the webinar to get insights from industry experts on the critical role of innovation in OTC products and strategies for achieving it, including key learnings from an industry survey, market trends from Nicolas Hall Companies and insights on technologies for creating innovative dosage forms. Fact Sheet: “New Cardio K2 Double Strength Vegicaps® Capsule with K2Vital” - Catalent and Kappa Bioscience have partnered to develop an innovative nutritional supplement for heart health. Introducing Cardio K2 Double Strength Vegicaps® Capsules. |
|
---|
| |
|
|
|
| Catalent Appoints Jim Walter as Vice President of Operations for Oral and Specialty Delivery
Jim Walter is appointed as Vice President of Operations for Catalent’s Oral and Specialty Delivery business. In the role, Mr. Walter Mr. Walter will have operational responsibility for five of the company’s facilities.
|
|
| |
|
|
| Catalent and Zumutor Biologics Collaborate to Manufacture First-in-Class mAb to Treat Solid Tumors
Catalent has signed an agreement with Zumutor Biologics, Inc., to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors. Zumutor is a biologics company that develops novel immuno-oncotherapeutics to drive transformational improvements in cancer treatment.
|
|
| |
|
|
| Catalent Recognized as a Country Certified Top Employer 2020 Catalent has officially been recognized by the Top Employers Institute as a Top Employer 2020 in the United States. Catalent employs over 13,000 people, including over 2,400 scientists and technicians and has 17 sites across the U.S.
|
|
| |
|
|
|
|
| | | At Catalent, you will have the opportunity to thrive in a fast-paced, innovative environment where maximizing your potential isn’t just your own personal goal, it’s ours too. Our teams are rapidly growing in Harmans, MD, Madison, WI, Schorndorf, Germany and multiple other locations. Apply today! Interested in working in Gene Therapy? Click here to view our openings. |
|
---|
| |
|
|
| Other Upcoming Expert Presentations and Events | |
|
|
|
|
|
| Every brand has a challenge. We have a solution. |
| | | | or call +1 877 891 9609 to speak with one of our experts today! |
| |
|
| To unsubscribe or manage your subscriptions, please click here. For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at [email protected], or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers. Catalent Pharma Solutions respects your privacy. Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement or the website, its owner(s) or the content. | © 2020, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved. |
|